CoChat

Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study

Open access
Dow, Coad Thomas, Harley, Calvin · 2016 · Clinical Ophthalmology

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Abstract

PURPOSE: Telomere attrition and corresponding cellular senescence of the retinal pigment epithelium contribute to the changes of age-related macular degeneration. Activation of the enzyme telomerase can add telomeric DNA to retinal pigment epithelium chromosomal ends and has been proposed as a treatment for age-related macular degeneration. We report the use of a small molecule, oral telomerase activator (TA)-65 in early macular degeneration. This study, focusing on early macular degeneration, provides a model for the use of TAs in age-related disease. METHOD: Thirty-eight (38) patients were randomly assigned to a 1-year, double-blinded, placebo-controlled interventional study with arms for oral TA-65 or placebo. Macular functions via micro-perimetry were the primary measured outcomes. RESULTS: The macular function in the arm receiving the TA-65 showed significant improvement relative to the placebo control. The improvement was manifest at 6 months and was maintained at 1 year: macular threshold sensitivity (measured as average dB [logarithmic decibel scale of light attenuation]) improved 0.97 dB compared to placebo (P-value 0.02) and percent reduced thresholds lessened 8.2% compared to the placebo arm (P-value 0.04). CONCLUSION: The oral TA significantly improved the macular function of treatment subjects compared to controls. Although this study was a pilot and a larger study is being planned, it is noteworthy in that it is, to our knowledge, the first randomized placebo-controlled study of a TA supplement.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/opth.s100042

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Change in percent reduced thresholds. Notes: (A) Box and whisker plot showing change in reduced thresholds for the intervention arm receiving TA-65 compared to placebo. (B) Line graph showing improvement as measured in mean change in reduced thresholds manifest at 6 months and continued at 12 months (P-value 0.04). Abbreviation: TA, telomerase activator.
Figure 1 Change in percent reduced thresholds. Notes: (A) Box and whisker plot showing change in reduced thresholds for the intervention arm receiving TA-65 compared to placebo. (B) Line graph showing improvement as measured in mean change in reduced thresholds manifest at 6 months and continued at 12 months (P-value 0.04). Abbreviation: TA, telomerase activator.CC BY-NC · PubMed Central
Figure 2 Change in average threshold. Notes: (A) Box and whisker plot showing change in average threshold for the intervention arm receiving TA-65 compared to placebo. (B) Line graph showing improvement as measured in average threshold (log dB of light attenuation) manifest at 6 months and continued at 12 months (P-value 0.02). Abbreviation: TA, telomerase activator.
Figure 2 Change in average threshold. Notes: (A) Box and whisker plot showing change in average threshold for the intervention arm receiving TA-65 compared to placebo. (B) Line graph showing improvement as measured in average threshold (log dB of light attenuation) manifest at 6 months and continued at 12 months (P-value 0.02). Abbreviation: TA, telomerase activator.CC BY-NC · PubMed Central
Figure 3 Montage of images from the right eye of patient number 13. Notes: (A) Photo of the posterior pole. (B) Optical coherence tomography showing drusen. (C) Micro-perimetry prior to study. (D) Macular function representation prior to study. (E) Micro-perimetry after 1 year of telomerase activator. (F) Macular function representation after 1 year of telomerase activator.
Figure 3 Montage of images from the right eye of patient number 13. Notes: (A) Photo of the posterior pole. (B) Optical coherence tomography showing drusen. (C) Micro-perimetry prior to study. (D) Macular function representation prior to study. (E) Micro-perimetry after 1 year of telomerase activator. (F) Macular function representation after 1 year of telomerase activator.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 56

Metadata

Authors
Dow, C. T., & Harley, C.
Affiliations
University of Wisconsin–Madison (US)
Corresponding author
Dow, Coad Thomas
Venue
Clinical Ophthalmology
Published
2016-01
Volume
10
Pages
243
ISSN
  • 1177-5467 (ISSN-L)
  • 1177-5483
OpenAlex
W2294620921
Cited by
56
References
56
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 10 · 2020: 9 · 2019: 3 · 2018: 4 · 2017: 1 · 2016: 3
FWCI
3.89
Type
journal article
Language
en
Open access
Locations
  • Clinical ophthalmology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
age-related macular degeneration, telomerase activators, retinal pigment epithelium, cellular senescence, telomere shortening, macular function, microperimetry, dietary supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.